While this T/C is still modest, it has been shown in the literature that only moderate efficacy can be achieved in mouse models with tolerated doses of MPS1 inhibitors as single agent in the models that have been tested (Colombo et al, 2010; Tardif et al, 2011; Laufer et al, 2014; Kusakabe et al, 2015; Maia et al, 2015), indicating that combination studies with standard-of-care may lead to a more successful use of MPS1 inhibitors in clinic in this particular type of cancer. This evidence concerns the gene TTK and cancer.